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Abstract 
Buckground andpurpose. To analyse the outcome, the treatment related side effects, the prognostic significance of clinical parame- 
ters in a group of patients with rectal cancer receiving postoperative radiotherapy after radical resection. Materials and methods. 
From 1980 to 1990 148 consecutive patients with rectal carcinoma stage B2-B3 or Cl-C2-C3 were treated with postoperative 
radiotherapy after radical surgery. All patients received 50 Gy in 25 sessions in 5 weeks. In 42 a ‘flash’ dose of 5 Gy was also given 
within 24 h before surgery. Median follow up was 8.1 years. Results. At 5 years the overall survival was 54%, the determined (cancer 
specific) survival al%, the local recurrence-free survival 88%. The influence of stage, histotype, distance from anal margin, type 
of surgery, number of involved nodes and flash dose were analysed. Overall and determined survival and distant metastasis rate 
were significantly influenced (P c 0.005) by the pathological stage. Patients with more than 3 involved nodes presented a 
significantly lower determined survival (P < 0.001) and a higher distant relapse rate (P c 0.005) than those with 3 or less involved 
nodes. Ahigher determined survival (P c 0.01) was also found in patients receiving the preoperative ‘flash’; this group was however 
unbal&ed in respect o the relative number of cases with 3 or less involved nodes. The incidence of major side effects requiring 
surgery or hospitalization for medical treatment was 35% before 1985 and 12% thereafter. The systematic use of small bowel 
visualization during simulation and the discontinuation of the flash dose were the main modifications introduced in the second 
period. As a consequence of the small bowel visualization the size of lateral fields was slightly reduced and some patients were 
excluded from the treatment. Concltlrion. Value of postoperative radiotherapy to decrease the incidence of local recurrence was 
confvmed in this retrospective study; the incidence of side effects was however considerable and did not support the addition of 
chemotherapy as advised by the NIH consensus meeting. Our policy was therefore moved to preoperative irradiation whose com- 
bination with chemotherapy was recently reported to be better tolerated and highly effective. 
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1. IxBtmwh 
Radiotherapy either pre or postoperative is widely 
accepted as the standard adjuvant treatment in rectal 
carcinoma invading the perktal tissues. A large range 
of doses was tested preoperatively ranging from a single 
fraction of 5 Gy within 24 h from surgery, to 45-50 Gy 
in 25 sessions [1,7,15,17,21,23,28,31,32,35,39,42,43, 
l Corresponding author. 
46,47,49,50,52-541. A more uniform dose around 50 Gy 
in 25 sessions was given when radiotherapy was used 
postoperatively [4,9,30,51,58-61,641. The main effect of 
radiotherapy was to decrease the incidence of local 
recurrence from 25-30% to lO- 15%; in some studies the 
time to relapse was also increased (41. To achieve this 
result preoperative radiotherapy must be given at a dose 
higher than 35 Gy if a conventional fractionation sched- 
ule of 1.8-2.0 Gy five times per week is used [a]. A 
shorter schedule of 20-25 Gy in 4-5 fractions in 5 days 
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has been proved to be equally effective [54]. The results 
of two randomized trials [34,57] also suggest hat 5- 
fluorouracil concomitant o postoperative radiotherapy 
may,prodFce a significant increase in the overall survival 
although at the expense of a higher morbidity and a 
lovver compliance. 
Whether radiotherapy is better to be given pre- or 
postoperatively is still controversial. The two options 
have been compared in a large randomized multicentric 
study in Sweden [45]: 471 consecutive patients with a 
respectable rectal carcinoma were randomized either to 
preoperative irradiation with a dose of 25.5 Gy in 5-7 
days (all patients were treated), or to postoperative irra- 
diation with a dose of 60 Gy in 8 weeks (only patients 
in pathological stage B2,Cl,C2 were treated); although 
survival was similar, the local recurrence rate was 
significantly lower in the preoperative group (12% vs. 
21%); a better compliance and a lower toxicity were also 
observed in this group. The result of the trial was 
therefore in favour of the preoperative option; in this 
group however irradiation was useless in 84 patients, 17 
because distant metastasis were detected at surgery and 
67 because the tumor was intraparietal (A,Bl). 
At the University Unit of Radiotherapy in Florence 
postbperative radiotherapy was routinely used from 
1980 to 1990 in 148 consecutive cases of rectal car- 
cinomas submitted to radical surgery and presenting a 
pathological &age B2-B3 or Cl-C2-C3 according to the 
Astler and Coller classification as modified by Gunder- 
son and Sosin. An update of the results obtained in this 
series after a minimum follow-up of 4 years is reported 
in this paper. These results represented the basis for 
changing our protocol to preoperative radiotherapy 
with concomitant 5-fluorouracil and folinic acid. 
2. Materials and metbods 
The main clinical characteristics of the patients are 
reported in Table 1. All patients were defined as 
‘radically resected’; this definition meant that there was 
no evidence of macroscopic residual tumor and that the 
proximal and distal surgical margins were micro- 
scopically free of tumor; the circonferential margins 
however were not systematically assessed. Surgery was 
an abdomino-perineal resection (APR) in 97, an ante- 
rior resection (AR) in 45; less typical surgical techniques 
were used in the remaining 6 cases. 
Table 2 reports the distribution of the histotype, of 
the type of surgery and of the distance from the anal 
ma@ according to the stage group (B2-B3 or Cl-C2- 
C3). ‘Out of the 28 cases presenting a G3 or a colloid 
tumor, a larger proportion (18 or 68%) were in C l-C2- 
C3 stage group, while the distance from the anal margin 
and the type of surgery were evenly distributed in the 
two stage groups. 
Before radiotherapy all patients were restaged with 
Table I 
Patients characteristics 
Total cases 
stage 
B2, B3 
Cl,C2,C3 
Sex 
males 
females 
Age (Y=rs) 
540 
41-50 
51-60 
61-70 
>70 
Distance from anal margin (cm) 
54 
S-10 
>I0 
not specified 
Histotype 
Gl 
G2 
G3 
colloid 
not specified 
SUWY 
APR 
AR 
other 
148 
13 
15 
88 
60 
6 
33 
44 
52 
13 
33 
12 
29 
14 
4 
105 
3 
21 
11 
97 
45 
6 
APR, abdomino-perineal resection; AR, anterior resection; other, 
radical surgery other than APR or AR. 
chest X-ray, abdominal ultrasound and CT. All patients 
were treated with a megavoltage linear accelerator (15 or 
25 MV) in prone position; a 4 fields box technique was 
used in the large majority of cases. The upper border of 
Table 2 
Distribution of the histotype, of the distance from anal margin and of 
the type of surgery according to the stage 
stage Broup 
B2,B3 Cl,C2,C3 
Histotype 
Gl 2 
G2 51 
G3 2 
colloid 8 
not speciiied 5 
SWWY 
APR 47 
AR 24 
other 2 
JMance from anal margin (cm) 
<5 16 
5-10 36 
>I0 15 
not specitkd 6 
2 
48 
5 
13 
6 
50 
21 
4 
17 
36 
14 
8 
APR, abdomino-perineal resection; AR, anterior resection; other, 
radical surgery other than APR or AR. 
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the radiation field was at the sacral promontory (Sl) in 
122 and at the LA/L5 junction in 26; the inferior border 
was at the inferior edge of the ischiatic bone in patients 
operated with an AR while the perineum was included 
in patients receiving an APR; the anterior border includ- 
ed in all cases the posterior bladder wall; it was extended 
to the posterior edge of the pubic symphysis when the 
vagina (6 cases, all of whom had a resection of the 
posterior vaginal wall) or the prostatic capsula (2 cases) 
were found to be involved by the tumor. The posterior 
border always included the sacral canal. Since 1985 
patients were simulated with opacification of the small 
bowel and patients in whom a large part of the presacral 
space on the lateral film was found to contain small 
bowel loops were not given irradiation. This resulted in 
the exclusion from the protocol of 7 cases (the number 
of patients included in the protocol was 60 in the period 
1985-90) because the risk of small bowel complications 
was considered to exceed the possible benefit on the 
local recurrence risk. The appreciation of amount of 
small bowel in the presacral space also resulted in a gen- 
eral reduction of the AP size of the lateral field. The 
dose was calculated at the intersection of the fields axis 
with a uniform weight from each portal; at least two 
fields were treated at each session; the total dose was 50 
Gy in 25 sessions in 5 weeks. In 42 cases, treated before 
June 1984 when the negative results of the MRC trial 
[17] were published, a flash dose of 5.0 Gy was also 
given within 24 h before surgery using 2 APIPA fields; 
there was no selection criteria for this patients group 
except for the fact that they were all referred from surgi- 
cal Departments located in our Hospital; the postopera- 
tive dose was in these cases 50 Gy in 25 sessions as in 
thownot receiving the preoperative flash. None of the 
patients received chemotherapy as a part of their adju- 
vant treatment. 
After the end of radiotherapy patients were regularly 
followed every 3 months for the first 2 years, every 6 
months up to the 5th year and yearly thereafter. The 
follow-up included clinical examination, CEA and liver 
US every 3 months for 3 years; every 6 months for the 
4th and the 5th year and every year thereafter. CT scan 
was performed every 6 months for the first 2 years; col- 
oscopy yearly. After 5 years in a few cases living at a 
large distance from our area the patient status was up- 
dated through the house doctor by phone interview. 
Overall 123 patients had a follow-up larger than 5 years 
(range 3-14 years; median 8 years). 
Relapses were classified as ‘local recurrence’ (LR) 
when they occurred inside the treated volume in the pel- 
vic area or in the perineum, as ‘distant metastases’ (DM) 
when they occurred in the abdomen outside the pelvis or 
in extrabdominal sites. The diagnosis of relapse was 
usually based on clinical or radiological evidence; in a 
few cases a pathological confirmation was felt necessary. 
All relapses were reported as a single event. 
Late side effects were scored as major when a surgical 
treatment was ,necessary or the medical treatment re- 
quired a prolonged hospitalization of the patient or 
when the complication resulted in the death of the 
patient. 
2.1. Statistics 
The life-table method was used to calculate probabili- 
ty of survival; the overall survival (OS), the determined 
(or cancer specific) survival (DS) and the local 
recurrence-free survival (LRFS) were calculated. Com- 
parison of survival curves was done using the log rank 
test. 
3. &Results 
The pattern of relapse is reported in Table 3 for the 
overall series and for the two stage groups. An LR was 
observed in 16 patients or 11% of the all series and a 
DM in 48 or 33%; 4 cases presented both an LR and a 
DM. The rate of LR was similar in the two stage groups; 
the DM rate was significantly higher in the group with 
involved nodes than in the group with negative nodes 
with a P < 0.005. 
The time to LR ranged from 3.6 to 113.4 months 
(mean 23.9 months). The OS, DS and LRFS at 5 and 10 
years were calculated for the all series and for the two 
stage groups and are reported in Table 4. In the all series 
the 5 years values were 54% for the OS, 61% for the DS 
and 88% for the LRFS. Both the OS and the DS were 
significantly higher in the group in stage B2-B3 than in 
that in stage Cl-C2-C3. The survival curves for the all 
series and the DS curves for the two stage groups are 
reported in Figs. 1 and 2. 
The pattern of relapse was not significantly affected 
by the type of surgery, by the histotype and by the dis- 
tance of the tumor from the anal margin (Table 5). The 
influence of the type of surgery on the probability of LR 
Table 3 
Pattern of relapse by stage group 
Total 
patients ; E 
Total series 148 
;:I%) 
48’ 
(33%) 
SW 
B2,B3 73 
(l%), 
n.s. 
I:,%), 
P < 0.005 
Cl,CZ,C3 15 10 ’ 31 ’ 
(13%) (41%) 
LR, local recurrence; DIM, distant metastasis. 
l 4 cases presented both LR and DM. 
n.s., statistically non-significant. 
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Table 4 
5 and 10 years actuarial survival values in the all series and by stage 
Survival values 
5 years IO years 
All series 
OS 
DS 
LRFS 
OS by stage 
B2,B3 - 
CI,C2,C3 
54% 45% 
61% 55% 
88% 81% 
71% 
37% 
DS by stage 
B2,B3 
CI,C2,C3 
77% 
45% 
68% . 
41% / p < 0.005 
LRFS by stage 
B2,B3 
Cl,C2,C3 
92% 81% \ 
84% 84% - n’s’ 
OS, actuarial overall survival; DS, actuarial determined (cancer speci- 
tic) survival; LRFS, actuarial local recurrence free survival; n.s., 
statistically non-significant. 
was examined in detail for the group of cases with tumor 
located below 10 cm; the use of AR did not appear in 
our series to be followed by a higher probability of LR; 
the LR probability was in fact 14% after an AR and 13% 
after an APR. In the group in stage Cl-C2-C3 the num- 
ber of involved nodes (3 or less vs. more than 3) was 
found to signifkantly affect the probability of DM and 
the OS and DS values (Table 6); the LRFS was also 
higher in the group with less involved nodes but not at 
a significant level. 
The survival values and the pattern of relapse of the 
patients group receiving the preoperative flash dose in 
addition to the postoperative irradiation were compared 
to those of the main group receiving the postoperative 
irradiation only (Table 7). The DS was significantly 
higher and the DM probability significantly lower in the 
60% - 
40% - 
s-m. (LRFS) 
. . . ..e (DS) 
20% - 
- (OS) 
0% 1 I 
0 12 3 4 6 6‘7 6 6 10 
)sur 
Fig. I. Survival curves for the whole patients group. APR. abdomino-perineal resection; AR, anterior resection. 
‘_“_- styIn;- 
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*-. . . . . . . . . . . . stage c 
40% . . . . . . . . . . . . . . . . . . . . . . . ..- v-n) 
2::. 
0 1 2 3 4 6 6 7 6 6 10 
Fig. 2. Determined survival curves for the two stages groups. 
former group; the OS value was also higher in this group 
but the difference was not statistically significant. The 
curves of DS in the groups with and without pre- 
operative flash are reported in Fig. 3. The analysis of the 
characteristics ofthe two groups (Table 8) revealed how- 
ever that the group receiving the flash dose had a 
relatively higher number of cases with 3 or less nodes 
compared to the group treated postoperatively only. 
Major late side effects were observed in 38 patients 
(26%). In 8 presenting chronic diarrhea and malabsorp- 
tion a hospitalization for medical treatment was 
required; a surgical treatment was necessary in the 
remaining30 patients (20%). Surgery was a lysis of intes- 
tinal adhesions in 8, an ileal resection or an ileo colic by- 
pass for a permanent ileal stenosis in 20, a colostomy for 
a rectal stenosis in 2 and a ureteroplasty for a fibrotic 
ureteral stricture in 2 (both also had a viscerolisis). Ten 
patients (6.7%) died because of complications related to 
Table 5 
Pattern of relapse according to the type of surgery, to the histotype 
.and to the distance from anal margin 
Total 
patients 
LR (%) DM (%) 
Type of surgery 
APR 97 
AR 45 
other 6 
Histotype 
colloid .2l 
non-colloid 127 
Distance from anal margin (cm) 
cs cm 33 
S-10 cm 72 
>I0 cm 29 
not specified I4 
6 (6%) 29 (30%) 
5 (11%) 14 (31%) 
l(l7%) I (17%) 
3 (14%) 6 (28%) 
I3 (lo%) 62 (33%) 
2 (6%) - 
IO (14%) - 
3 (10%) - 
I (7%) - 
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Table 6 
Pattern of relapse and 5 years actuarial survival values in stage C by 
number of involved nodes 
Number of involved nodes 
$3 (42) > 3 (26) 
Pattern of relapse 
LR 4 (9%) 6 (23%) n.s. 
DM 12 (29%) 16 (61%) P c 0.005 
Survival values 
OS 56% 29% P < 0.005 
DS 64% 30% P < 0.001 
LRFS 89% 13% n.s. 
OS, actuarial overall survival; DS, actuarial determined (cancer speci- 
fic) survival; LRFS, actuarial ocal recurrence-free survival; LR, local 
recurrence; DM, distant metastasis; n.s., statistically non-significant. 
these side effects without evidence of disease. In 6 
patients the death occurred because of a perioperative 
complication (usually perforation and peritonitis) short- 
ly after the operation performed for a small bowel 
obstruction. In all of these cases surgery was done in an 
emergency unit of another hospital where surgeons were 
not aware of the previous treatment of the patient. 
Three patients died because of malabsorption after 
extensive ileal resection and 1 because of rectal hemor- 
rhage. All deaths and the majority of major complica- 
tions occurred during the early period of our experience. 
The incidence of major side effects was in fact 35% in the 
period from 1980 to 1985 and 12% after 1985. The main 
modifications introduced in the second period were the 
exclusion of the preoperative flash dose, and the in- 
troduction of the small bowel visualization for the simu- 
lation procedure; this last measure resulted in a more 
careful selection of the lateral fields size and in the exclu- 
sion from irradiation of some cases with a larger amount 
Table I 
Actuarial 5-years urvival values and pattern of relapse in the patient 
group receiving the pre-operative flash; comparison with the group 
treated post-operatively only 
Pm-operative flash dose 
Yes (42 pts.) No (106 pts.) 
survival vahes 
OS 64% 50% n.s. 
DS 78% 55% P < 0.01 
LRFS 92% 87% n.s. 
Pattern of relapse 
LR 3 (7%) 13 (120/o) n.s. 
DM 8 (19%) 41 (39%) P < 0.01 
OS, actuarial overall survival; DS, actuarial determined (cancer speci- 
fic) survival; LRFS, actuarial ocal recurrence-fre-e survival, LR, local 
recurrence; DM. distant metastasis; n.s., statistically non-significant. 
100% 
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Fig. 3. Determined survival curves for the groups receiving the 
preoperative flash or treated postoperatively only. 
of small bowel in the presacral space. Table 9 reports the 
correlation of type of surgery, preoperative flash dose, 
position of the upper border of the treated area and 
period of treatment with the incidence of major side 
effects. The period of treatment before or after 1985 was 
the only significant factor. A considerable increase of 
major side effects was also observed in the group of 
patients receiving the preoperative flash dose. 
4. Discussion 
A large number of papers have been published in the 
last 20 years reporting the results of postoperative 
radiotherapy in rectal cancer; in four [3,18,57,58] post- 
operative radiotherapy was compared in a randomized 
trial with surgery only; in some papers [10,30,38,42, 
56,601 there was a historical comparison with a previous 
series treated with surgery only; in most [9,13,14,16, 
24,40,51,62-641 there was no control series and the re- 
sults were compared with those of the current surgical 
literature. In all studies patients receiving postoperative 
Table 8 
Distribution by stage and by number of involved nodes in the group 
receiving the pre-operative flash dose and in the group treated post- 
operatively only 
Pre-operativc flash dose 
Yes (42 pts.) No (106 pts.) 
SUP 
BZ,B3 21 (50%) 52 (49%) 
Cl,CZ,C3 21 54 
No. of involved nodes 
$3 14 (67%) 28 (52%) 
>3 5 (24%) 21 (39%) 
not specified 3 (14%) 5 (9%) 
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Table 9 
Type of surgery, pre-operative flash dose, level of the upper field 
border and period of treatment in patients presenting major late side 
effects 
Total 
patients 
No. with major side effects (%) 
Type of surgery 
APR 97 
AR and other 51 
25 (26%) \n s 
I3 (25%)’ . 
Pre-op. flash dose 
Yes 42 I4 (33%). 
No I06 24 (23%), ‘A 
Upper field border 
L5-SI 122 30 (25%). 
L4-LS 26 8 (31%)~n’s’ 
Period of treatment 
1980-85 88 31 (35%). 
1986-90 60 1(12%) 
/P < 0.005 
APR, abdomino-perineal resection; AR, anterior resection; other, 
radical surgery other than APR or AR; n.s., statistically non- 
significant. 
radiotherapy had perirectal infiltration and/or positive 
nodes. A higher (although not statistically significant) 5 
years OS was reported with postoperative radiotherapy 
(46% vs. 36% with surgery only) in the randomized trial 
carried out by the Gastrointestinal Tumor Study Group 
first published in 1985 [22] and updated in 1988 [57] 
with an 8 years follow-up; no advantage was observed 
in the other 3 studies. The incidence of LR was lower 
(although not at a statistically significant level) after 
postoperative irradiation than after surgery only, in 3 of 
the 4 randomized trials and in all studies with a histori- 
cal control; values of LR lower than generally expected 
after surgery only were also reported in all of the studies 
without a control arm. Acute side effects of postopera- 
tive radiotherapy required the early stop of treatment in 
a considerable number of cases, According to the review 
of Bosset and Horiot [6] in the published trials of post- 
operative radiotherapy 12-27% of patients did not re- 
ceive the full planned dose. Late side effects after 
postoperative irradiation were also definitely higher 
than after surgery only. Up to 20-30% of the irradiated 
patients experienced complications requiring some mod- 
ification of their life style (diet, intestinal function, sex- 
ual function, bladder function); from 5-15% presented 
major complications essentially affecting the small 
bowel (adhesion, stenosis, malabsorption) requiring 
hospitalization for medical treatment or a surgical treat- 
ment; from 2-5% had a treatment related death. In the 
Swedish trial [20] 41% of patients undergoing postoper- 
ative irradiation with 60 Gy in 8 weeks, experienced 
complications possibly related to radiotherapy com- 
pared to 23% of a historical control group treated by 
surgery only. In the Danish Trial [4] severe complica- 
tions were reported in 21% of cases receiving postopera- 
tive radiotherapy vs. 8.4% for the group treated by 
surgery only. A frequency of bowel obstruction requir- 
ing surgery between 4% and 13% was also reported after 
postoperative radiotherapy in a number of studies 
without a control arm [7,29,55,57,60,61]. Letschert [36] 
in a retrospective r view of 111 cases treated with radia- 
tion after rectal surgery, found a dose volume correla- 
tion for small bowel complications; the incidence of 
severe small bowel complications was 37% when 2 
AP/PA large fields were used and 6% for limited three- 
field technique. The bowel function was assessed in 
detail by Kollmorgen et al. [33] in a group of 100 cases 
with a minimum of 2 years follow-up after anterior 
resection of the rectum; 41 received postoperative 
chemoradiation, while 59 were only operated; night time 
bowel movements were present in 46% in the first group 
vs. 19% in the second, occasional incontinence in 39% 
vs. 17%, fecal urgency in 78% vs 19%. 
The LR rates reported after postoperative 
radiotherapy in the studies reviewed are between 6% and 
25%. In our series the incidence of LR was evaluated 
both by dividing the number of LR observed and the 
total number of patients and by the actuarial curves of 
LRFS at 5 years. All our values are within the more 
favourable end of the range reported in the literature 
and support the opinion that postoperative radio- 
therapy is able to significantly reduce the incidence of 
local relapses in the pelvis. 
The actuarial 5 years overall survival in the same liter- 
ature series range between 40% and 55% and our value 
of 53.8% is within this range. Similar survival figures are 
however reported in several surgical series for the 
Duke’s stages B and C. The value of postoperative 
radiotherapy on survival in rectal cancer therefore 
remains still unproven. 
The prognostic significance of the main 
characteristics of the patient, of the disease and of the 
treatment were also assessed in our series. The 
pathological stage was confirmed as the first prognostic 
factor for survival; the worse prognosis of C cases was 
due to the much higher incidence of DM while the inci- 
dence of LR was very similar than in B cases. The num- 
ber of positive nodes was also found to have a 
significant prognostic value suggesting the differentia- 
tion of two subtypes of stage C, with 3 or less and with 
more than 3 involved nodes. This factor turned out to 
affect the risk of DM and not the risk of LR. The prog- 
nostic value of the number of involved nodes in rectal 
cancer was already reported in the literature. In their 
series ubmitted to systematic second look after primary 
curative surgery, Gunderson et al. had more than 3 
nodes involved in 22 of the 40 patients presenting a fail- 
ure and only in 3 of the 20 remaining disease free; the 
site of failure was however not specified. In the GITSG 
series [34] the number of involved nodes was mentioned 
as one of the independent determinants of DM but not 
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of LR. In the Mayo Clinic series published by Schild et 
al. [Sl] a number of involved nodes was associated with 
a higher incidence of DM and a lower survival, while the 
incidence of LR was similar than in the group with less 
than 4 nodes involved. No prognostic relevance was 
found for the distance from the anal margin, for the 
histotype and for the type of surgery. 
The use of a flash dose of 5 Gy within 24 h before the 
operation followed by postoperative irradiation was 
reported in a few series [5,8,10,25,26,37,52,63]; in none 
of them was there a randomized comparison and the 
number of cases treated was always quite small. The re- 
sults of these studies, although very favourable, cannot 
therefore be validated. Furthermore, negative results 
have been reported in a large randomized trial carried 
on by the MRC [17] demonstrating the absence of any 
effect when the flash dose was used alone. In our series 
the use of the preoperative flash, although not rando- 
mixed, was not intentionally selected for any factor and 
it was stopped after the publication of the negative result 
of the MRC trial. It was therefore very surprising to 
discover at the initial analysis of our series that there 
was a statistically significant advantage for DS in the 
group receiving the preoperative flash with respect o 
the group only receiving the postoperative irradiation. 
This advantage in survival was due to a lower incidence 
of DM supporting the hypothesis that the flash dose 
might decrease the viability of cells disseminated uring 
the surgical manipulation. Further analysis of the two 
groups demonstrated however that the distribution of 
one of the two prognostic factors, the number of posi- 
tive nodes, was unbalanced in favour of the group 
receiving the preoperative flash. Whether this can fully 
explain the observed difference cannot be stated but it 
certainly introduces a considerable bias and it does not 
allow to support the value of the flash dose. 
The incidence of serious complications was higher 
than reported in the recent literature in the early phase 
of our study. The main reason was that the un- 
favourable influence of rectal surgery on the tolerance of 
small bowel to radiation was not sufficiently appreciated 
at that time. The complications rate decreased in fact 
from 35.2% to 11.7% when we started to evaluate 
systematically the amount of small bowel in the ir- 
radiated volume and the use of the flash dose was stop- 
ped. Our experience also demonstrated that both the 
patient and the family doctor should be carefully in- 
formed of the potential risks of this treatment. It is likely 
that some deaths occurring after an emergency opera- 
tion with extensive resection and multiple anastomoses 
‘of adherent loops for an intestinal occlusion, were 
avoidable if the patient was referred to us at the first ap- 
pearance of symptoms and not sent to a peripheral hos- 
pital when he was already in critical condition. These 
cases are in fact often better managed with medical 
treatment and less aggressive surgery. 
The lower but still considerable incidence of side ef- 
fects observed with postoperative radiotherapy even 
after this measure, made us reluctant to start the com- 
bination with chemotherapy as advised by the NIH con- 
sensus meeting [44]; although justified by the attempt o 
decrease the number of DM, this approach was in fact 
reported to be followed by a higher number of complica- 
tions and a lower compliance. 
Based on the better tolerance reported for pre- 
operative radiotherapy [2,6,20,45] and on the 
favourable results obtained with the combination of 
radio and chemotherapy in tethered or inoperable 
tumors [11,12,19,27,41,48] our policy has now been 
moved to the use of preoperative irradiation with con- 
comitant chemotherapy (5 fluorouracil and folinic acid); 
this treatment is reserved to patients with tumors arising 
in the extraperitoneal portion of the rectum and staged 
as T3 by digital examination (tethered or fixed) or/and 
by endorectal ultrasound or RM. This seems at present 
the best approach to be tested in locally advanced rectal 
cancer to improve the patients survival with less mor- 
bidity. 
References 
111 
PI 
I31 
141 
151 
161 
[71 
181 
191 
w 
Ahmad, N.R., Marks, G. and Mohiuddin, M. High dose 
preoperative radiation for cancer of the rectum: impact of radia- 
tion dose on patterns of failure. and survival. Int. J. Radiat. 
Oncol. Biol. Phys. 27: 773-778, 1993. 
Ardiet, J.M., Coquard, R., Romestaing, P., Fric, D., Baron, 
M.H., Rocher, F.P., Sentenac, I. and Gerard, J.P. 
Radiotherapie du carcinomes du bas rectum. Bull. 
CancerRadiother. 81: 285-291. 1994 
Baslev, I., Pedersen, M. and Teglbjaerg, P.S. Postoperative 
radiotherapy in Dukes B and C carcinoma of the rectum and 
rectosigmoid. A randomized multicentric study. Cancer 58: 
22-28, 1986. 
Baslev, I., Pedersen, M., Teglbjaerg, P.S., Hanberg Sorensen, 
F., Bone, J., Jacobsen, N.O., Overgaard, J., Bertelsen, K., Hage, 
E., Hansen, L., Rronborg, O., Hostrup, H. and Norgaard 
Pedersen, B. Postoperative radiotherapy in rectosigmoid cancer 
Dukes B and C: interim report from a randomized multicentric 
study. Br. J. Cancer 46: 551-556, 1982. 
Bayer, I., Turani, N., Lurie, H. and Chamoff, C. The sandwich 
approach: irradiation, surgery, irradiation in rectal cancer. Dis. 
Colon Rectum 28: 222-224, 1985. 
Bosset, J.F. and Horiot, J.C. Adjuvant treatment in the curative 
management of rectal cancer: a critical review of the results of 
clinical randomized trials. Eur. J. Cancer 29A: 770-774, 1993. 
Boulis Wassif, S. The role of preoperative adjuvant therapy in 
the management of borderline operable rectal cancer. Clin. 
Radiol. 33: 353-358, 1982. 
Brenner, S., Lamer, B. and Seligman, S.B. Adjuvant therapy in 
treatment of rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 
6: 1378, 1980. 
Brizel, H.E. and Tepperman, B.S. Postoperative adjuvant irradi- 
ation for adenocarcinoma of the rectum and sigmoid. Am. J. 
Oncol. 7: 679-685, 1984. 
Cellini, N., Valentini, V., De Santis, M., Morganti, A.G., 
Trodella, L., Coca, C., Picciocchi, A. and Dobelbower, R.R. Jr. 
Radiosurgical treatment compared to surgery alone for rectal 
cancer. Int. J. Radiat. Oncol. Phys. 19: 1159-1164, 1990. 
134 L. Cionini et al. /Radiotherapy and Oncology 40 (19%) 127-135 
[l I] Chan, A., Wang, A., Lang&n, J. and Khoo, R. Preoperative 
concurrent 5Fluorouracil infusion, Mytomicin C and pelvic ra- 
diation therapy in tethered and fixed rectal carcinoma. Int. J. 
Radiat. Oncol. Biol. Phys. 25: 791-799, 1993. 
[12] Chen, E.T., Mohiuddin, M., Brodovsky, H., Fishbein, G. and 
Marks, G. Downstaging of advanced rectal cancer following 
combined preoperative chemotherapy and high dose radiation. 
Int. J. Radiat. Oncol. Biol. Phys. 30: 169-175, 1994. 
[13] Cohen, Y. The treatment of rectosigmoid cancer by surgery, 
radiotherapy and chemotherapy. Digestion 16: 235, 1977. 
[14] Coquard, R., Romestaing, P., Buatois, F., Rocher, F., Berger; 
C., Mahe, M., Dupeuple, M.Th., Sentenac, I. and Gerard, J.P. 
La radiotherapie postoperatoire des cancers du rectum. L’expe- 
rience Lyonnaise. A propos de 177 cas Lyon Chir. 89: 333-338, 
1993. 
[15] Dahl, O., Horn, A., Morild, I., Halvorsen, J.F., Odland, G., 
Reissertsen, S., Reisaeter, A., Kavli, H. and Thunold, J. Low 
dose preoperative radiation postpones recurrences in operable 
rectal cancer. Cancer 66: 2286-2294, 1990. 
[I61 Devereux, D.F., Eisenstat, T. and Zinkin, L. The safe and effec- 
tive use of postoperative radiation therapy in modified Astler 
Colles stage C3 rectal cancer. Cancer 62: 2393-2396, 1989. 
[I71 Duncan, V. The evaluation of low dose preoperative X-ray ther- 
apy in the management of operable rectal cancer: results of ran- 
domly controlled trial. Br. J. Surg. 71: 21-25, 1984. 
[18] Fisher, B., Wohnark, N., Rockette, H., Redmond, C., Deutsch, 
M., Wickerham, D.L., Fisher, R.E., Caplan, R., Jones, J., 
Lemer, H., Gordon, P., Feldman, M., Crux, A., Legault- 
Poisson, S., Wexler, M., Lawrence, W., Robidoux, A. and other 
NSAB investigators. Postoperative adjuvant chemotherapy or 
radiation therapy for rectal cancer: rest&s from NSAB protocol 
R-01. J. NatI. Cancer Inst. 80: 21-29, 1988. 
1191 Frykholm, G.J., Glimelius, B. and Pahhnan, L. Preoperative ir- 
radiation with and without chemotherapy in the treatment of 
primarily unresectable adenocarcinoma of the rectum. Eur. J. 
Cancer Clin. Oncol. 25: 1533-1541, 1989. 
[20] Frykhohn, G.J., Glimelius, B. and Pahhnan, L. Preoperative or 
postoperative irradiation in adenocarcinoma of the rectum: final 
treatment results of a randomized trial and evaluation of late 
secondary e&cts. Dis. Colon Rectum 36: 564-572, 1993. 
[21] Galloway, D.J., Cohen, A.M., Shank, B. and Friedman, M.A. 
Adjuvant multimodality treatment of rectal cancer. Br. J. Surg. 
76: 440447, 1989. 
[22] Gastrointestinal Tumor Study Group. Prolongation of the 
disease free interval in surgically treated rectal carcinoma. N. 
Engl. J. Med. 312: 1466-1472, 1985. 
[23] Gerard, A., Buyse, M., Nordhnger, B., Lo&e, L., Pene, F., 
Kempf, P., Basset, J.F., Gignoux, M., Amaud, J.P., Desaive, C. 
and Duex, M. Preoperative radiotherapy as adjuvant treatment 
in rectal cancer. Final results of a random&d study of the 
EORTC Gastrointestinal Tract Cancer Cooperative Group. 
Ann. Surg. 208: 606-614, 1988. 
[24] Ghossein, N.A., Ager, P.G., Ragins, H., Turner, S., De Luca, 
S., Alpert, S. and Lowi, S.J. The treatment of locally advanced 
carcinoma of the colon and rectum by a surgical procedure and 
radiotherapy postoperatively. Surg. Gynec. Obstet. 148: 
917-920, 1979. 
[ZS] Girshovich, L., Leibenhaut, M.H. and Saixman, F.A. Sandwich 
radiotherapy for carcinoma of the rectum. Second International 
Conference on Gastrointestinal Cancer, Jerusalem, 27 August-l 
September, pp. 13, 1989. 
[26] Gunderson, L.L., Dosoretx, D.E., Hedberg, S.E.. Blitxer, P.H., 
Rodkey, G., Hoskins, B., Shipley, W.U. and Cohen, A.C. Low 
dose preoperative irradiation, surgery and elective postoperative 
radiation therapy for resectable rectum and rectosigmoid car- 
cinoma. Cancer 52: 446-451, 1983. 
1271 Haghbin, M., Sischy, B. and Hinson, J. Combined modality 
preoperative therapy in poor prognostic rectal adenocarcinoma. 
Radiother. Oncol. 13: 75-81, 1988. 
[28] Higgins, G.A., Humphrey, E.W., Juler, G.L., Roswit, B. and 
Keehn, R.J. Adjuvant therapy for rectal cancer. Update of 
Veterans Administration Surgical Oncology Group trials. In: 
Progress and perspectives in the treatment of gastrointestinal 
tumors, pp. 62-67. Pergamon Press, Oxford, 1981. 
1291 Hoskins, B., Gunderson, L., Dosoretx, D., Rich, T.A., 
Galdabini, S., Donaldson, G. and Cohen, A.M. Adjuvant post- 
operative radiotherapy in carcinoma of the rectum and rec- 
tosigmoid. Cancer 55: 61-71, 1985. 
[30] Janoray, P., Faivre, J., Milan, C., Horiot, J.C., Klepping, C., 
Koekhn, M. and Ledotze, C. La radiotherapie postoperatoire 
des cancers du rectum. Gastroenterol. Clin. Biol. 7: 451-456, 
1983. 
[31] Jones, D.J., Zalondik, J., James, R.D., Haboubi, N., Moore, M. 
and Schofield, P.F. Predicting local recurrence of carcinoma of 
the rectum after preoperative radiotherapy and surgery. Br. J. 
Surg. 76: 1172-1175, 1989. 
[32] Kodner, I.J., Shemesh, E.J., Fry, R.D., Walx, B.J., Myerson, R., 
Fleshman, J.W. and Schechtman, K.B. Preoperative irradiation 
for rectal cancer improved local control and long term survival. 
Ann. Surg. 209: 194-199, 1989. 
[33] Kollmorgen, C.F., Meagher, A.P., Wolf, B.C., Pemberton, J.H. 
and Martenson, J.A. The long term effect of adjuvant postoper- 
ative chemoradiotherapy for rectal carcinoma on bowel func- 
tion. Ann. Surg. 220: 676-679, 1994. 
[34] Krook, J.E. and Moertel, C.G. et al. Surgical adjuvant therapy 
for high risk rectal carcinoma. N. Engi. J. Med. 324: 709-715, 
1991. 
[35] Leaming, H.R. Radiation therapy in the clinical management of 
neophtsms of colon rectum and anus. In: Neoplaams of the 
colon rectum and anus, pp. 143-153. J. Wiley and Sons, New 
York, 1980. 
[36] Letschert, J.G.J., Lebesque, J.V., de Boer, R.W., Hart, A.A.M. 
and Barteliink, H. Dose volume correlation in radiation related 
late small bowel complications: a clinical study. Radiother. 
Oncol. 18: 307-320, 1990. 
[37] Lingareddy, V., Mohiuddin, M. and Marks, G. The importance 
of patients election for adjunctive postoperative radiation ther- 
apy for cancer of the rectum. Cancer 73: 1805-1810, 1994. 
(381 Locaho, S.A., Nealon, W., Newall, J. and Valensi, Q. Adjuvant 
postoperative radiation therapy for Dukes C adenocarcinoma of
the rectum. Ann. Surg. 198: 18-24, 1983. 
1391 Mendenhall, W.M., Bland, K.I., Rout, W.R., PfaIT, W.W., 
Million, R.R. and Copeland, E.M. Clincahy resectable adeno- 
carcinoma of the rectum treated with preoperative irradiation 
and surgery. Dis. Colon Rectum 31: 287-290, 1988. 
[40] Mendiondo, O.A., Wang, C.C.. Welch, J.P. and Donaldson, 
G.A. Postoperative radiotherapy in carcinomas of the rectum 
and distal sigmoid colon. Radiology 119: 673-676, 1976. 
[41] Minsky, B.D., Kemeny. N., Cohen, A.M., Enker, W.E., Kelsen, 
D.P., Reichman, B., Sal& L., Sigurdson, E.R. and Frankel, J. 
Preoperative high dose leucovorin/Fhtorouraciacil and radiation 
therapy for unresectable rectal cancer. Cancer 67: 2859-2866, 
1991. 
[42] Mohiuddin M.. Derdel, J., Marks, J. and Kramer, S. Results of 
adjuvant radiation therapy in cancer of the rectum. Thomas Jef- 
ferson University Hospital experience. Cancer 55: 350-353, 
1985. 
[43] Myerson, R.J. Adjunctive radiation therapy for rectal car- 
cinoma. Am. J. Clin. Oncol. 15: 102-111, 1992. 
[Sq] NIH Conference. Adjuvant therapy for patients with colon and 
rectal cancer. J. Am. Med. Assoc. 264: 1444-1449,199O. 
[45] Pahhnan, L. and Glimelius, B. Pre or postoperative 
radiotherapy in rectal and rectosigmoid carcinoma. Ann. Surg. 
211: 187-195, 1990. 
L. Cionini er al. /Radiotherapy and Oncology 40 (19%) 127-135 135 
WI 
I471 
WI 
[491 
WI 
WI 
WI 
I531 
WI 
Reed, W.P., Garb, J.L., Park, WC., Stark, A.J., Chabot, J.R. 
and Friedman, T. Long term results and complications of 
preoperative radiation in the treatment of rectal cancer. Surgery 
103: 161-167, 1988. 
Reis Neto, J.A., Quilice, E.A. and Reis, J.A. Jr. A comparison 
of non-operative versus preoperative radiotherapy in rectal car- 
cinoma. Dis. Colon Rectum 32: 702-710, 1989. 
Rich, T., Skibber. J., Ajani, J., Bucholx, D., Cleary, K., 
Dubrow, R., Levitt, B., Lynch, P., Meterissian, S., Roubein, L. 
and Ota, D.M. Preoperative infusional chemoradiation for stage 
T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 32: 
1025-1029, 1995 
Rider, W.D., Palmer. J.A., Mahoney, L.J. and Robertson, CT. 
Pnoperative irradiation in operable cancer of the rectum: report 
of the Toronto trial. Can. J. Surg. 20: 335-358, 1977. 
Roswit, B., Higgins, G.A. and Keen, R.J. Preoperative irradia- 
tion for carcinoma of the rectum and rectosigmoid colon: report 
of a National Veterans Administration randomized study. 
Cancer 35: 1597-1602, 1975. 
Schild, S.E., Martenson, J.A., Gunderson, L.L., Ilstrup, D.M., 
Berg, K.K., D’Connel, M.J. and Weiland, L.H. Postoperative 
adjuvant herapy of rectal cancer: an analysis of disease control, 
survival and prognostic factors. Int. J. Radiat. Oncol. Biol. 
Phys. 17: 55-62, 1989. 
Shank, B., Enker, W., Santana, J., Morrissey, K., Daly, J., 
Quart, S. and Knapper, W. Local control with preoperative 
radiotherapy alone versus ‘sandwich’ radiotherapy for rectal 
carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 13: 1 l-115, 1987. 
Stevens, K.R., Allen, C.V. and Fletcher, W.S. Preoperative 
radiotherapy for adenocarcinoma of the rectosigmoid. Cancer 
37: 2866-2874, 1976. 
Stockholm Rectal Cancer Study Group. Preoperative short term 
radiation therapy in operable rectal carcinoma. Cancer 66: 
49-55. 1990. 
[551 
t5’51 
I571 
1581 
1591 
WI 
WI 
WI 
(631 
WI 
Tang, R., Wang, J.Y ., Chen, J.S., Chang-Chien, C.R., Lin, SE., 
Leung, S. and Fan, H.A. Postoperative adjuvant radiotherapy 
in Astler-Coller stages B2 and C rectal cancer. Dis. Colon Rec- 
tum 35: 1057-1065, 1992. 
Tepper, J.E. Radiation therapy of colorectal cancer. Cancer 51: 
2528-2534, 1983. 
Thomas, P.R.M. and Lindblad, A.S. Adjuvant postoperative 
radiotherapy and chemotherapy in rectal carcinoma: areview of 
the GITSG experience. Radiother. Gncol. 13: 245-252, 1988. 
Treuniet-Donker, A.D., Van Putten, L.J., Wereldsma, J.C., 
Bruggink, D.M., Hoogenraad, W.J. and Rokema, J.A. Postop- 
erative radiation therapy for rectal cancer. An interim analysis 
of a perspective randomized trial in the Netherlands. Cancer 67: 
2042-2048. 1991. 
Tepper, J.E., Cohen, A.M., Wood, W.C., Orlow, E.L. and 
Hedberg, S.H. Postoperative radiation therapy of rectal cancer. 
Int. J. Radiat. Gncol. Biol. Phys. 13: 5-10, 1987. 
Vigliotti, A., Rich, T.A., Romsdahl, M.M., Withers, H.R. and 
Oswald, M.J. Postoperative adjuvant radiotherapy for adeno- 
carcinoma of the rectum and rectosigmoid. Int. J. Radiat. 
Oncol. Biol. Phys. 13: 999-1006, 1987. 
Wiggenraad, R., Ravaxs, L.A. and Probst-Van Zuylen, F.E. Ad- 
juvant postoperative radiotherapy for carcinoma of the rectum 
and rectosigmoid. Int. J. Radiat. Oncol. Biol. Phys. 15: 
753-756, 1988. 
Wiggenraad, R., Ranting, M., Hermans, J., Biesta, J., Hoekstra, 
F. and De Jager-Novak, H. Postoperative local radiotherapy in 
rectal cancer: treatment results with limited radiation fields. Int. 
J. Radiat. Qncol. Biol. Phys. 27: 785-790, 1993. 
Winkler, R. Adjuvant radiotherapy in rectosigmoid cancer. 
Zentraib. Chir. 110: 124-136, 1985. 
Zucali, R., Gardani, G. and Lattuada, A. Adjuvant irradiation 
after radical surgery of the rectum and rectosigmoid. Radiother. 
Oncol. 8: 19-24, 1987. 
